• BZDS1901 CAR-T therapy shows frequent tumour responses, including complete clearance, in advanced mesothelioma patients
• Manufacturing transferred to Australia, enhancing strategic value and future scalability
• $1.2 million raised via private placement to support 'East-to-West' strategy

AdAlta Limited (ASX:1AD) has reported promising results for its BZDS1901 CAR-T therapy in patients with advanced mesothelioma, a cancer with historically poor treatment options. Early studies in China have shown BZDS1901 achieving up to 50% overall response rates and 20% complete response rates, where tumours were fully cleared. Notably, one complete responder remains alive 22 months after treatment with no reported recurrence. These outcomes are highly significant in this difficult-to-treat cancer. AdAlta has also made substantial progress in transferring BZDS1901 manufacturing to Australia, which will support future clinical trials and enhance the therapy's strategic value and scalability. The company has signed an MoU with partners to access next-generation automated manufacturing technology, aiming to drive further improvements in cost, speed and success rates. AdAlta raised $1.2 million via a private placement during the quarter to accelerate its 'East-to-West' strategy of bringing promising Asian cell therapies to Western markets using Australian expertise.

AdAlta is focused on progressing its 'East-to-West' cellular immunotherapy strategy, including further development of the BZDS1901 CAR-T therapy for mesothelioma. The company is also seeking to monetise its i-body enabled assets, such as AD-214 for fibrosis and WD-34 for malaria.